miR-122 Promotes Hepatic Lipogenesis via Inhibiting the LKB1/AMPK Pathway by Targeting Sirt1 in Non-Alcoholic Fatty Liver Disease

Molecular Medicine - United States
doi 10.1186/s10020-019-0085-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Genistein Ameliorates Non-Alcoholic Fatty Liver Disease by Targeting the Thromboxane A2 Pathway

English

Chinese Herbal Formula (CHF03) Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) Through Inhibiting Lipogenesis and Anti-Oxidation Mechanisms

Frontiers in Pharmacology
Pharmacology
2019English

The Role of Dietary Sugars and De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease

Nutrients
NutritionFood ScienceDietetics
2014English

SIRT1 Promotes Endometrial Tumor Growth by Targeting SREBP1 and Lipogenesis

Oncology Reports
MedicineCancer ResearchOncology
2014English

Mechanism of Hepatic Insulin Resistance in Non-Alcoholic Fatty Liver Disease

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2004English

Hepatic Lipogenesis and Mobilization of Peripheral Fats in the Formation of Alcoholic Fatty Liver.

The Japanese Journal of Pharmacology
1981English

Radix Polygoni Multiflori and Its Main Component Emodin Attenuate Non-Alcoholic Fatty Liver Disease in Zebrafish by Regulation of AMPK Signaling Pathway

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2020English

Metformin Inhibits Hepatic Gluconeogenesis in Mice Independently of the LKB1/AMPK Pathway via a Decrease in Hepatic Energy State

Journal of Clinical Investigation
Medicine
2010English

Adiponectin Promotes Pancreatic Cancer Progression by Inhibiting Apoptosis via the Activation of AMPK/Sirt1/PGC-1α Signaling

Oncotarget
Oncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy